shopping cart
nothing in cart
 
browse by subject
new releases
best sellers
sale books
browse by author
browse by publisher
home
about us
upcoming events
Jan 24th - Cognitive behaviour therapy (CBT) for post-traumatic stress disorder (PTSD) with prolonged exposure (PE) therapy [SickKids CCMH Learning Institute]
Jan 24th - Becoming Whole Again: Psychedelic-Assisted Psychotherapy for Trauma [Leading Edge Seminars]
Jan 27th - Creative interventions for children with ADHD [SickKids CCMH Learning Institute]
Jan 27th - Certificate in cognitive behaviour therapy (CBT) level 1: The foundations [SickKids CCMH Learning Institute]
Jan 28th - Supporting the mental health needs of racialized young people [SickKids CCMH Learning Institute]
schools agencies and other institutional orders (click here)
Now open for browsing 12-6 Mon-Sat and 12-5 Sunday for three people at a time. Pickups still from 9 to 6, Monday to Saturday. Free shipping across Canada for orders over $100. Please read our Covid-19 statement here.
Join our mailing list! Click here to sign up.
Management of Complex Treatment-Resistant Psychotic Disorders
Michael Cummings and Stephen Stahl (Eds)
Cambridge University Press / Softcover / 2021-06-01 / 1108965687
Psychopharmacology
price: $56.95
304 pages
In Stock (Ships within one business day)

This full-color, practical handbook provides a concise, evidence-based psychopharmacological approach to the management of complex treatment-resistant psychotic disorders. Part I focuses uniquely on topics and strategies relevant to treating this challenging patient population. These approaches go beyond standard guidelines while adhering to research and clinically derived data. Part II provides a concise array of information regarding those classes of medications most commonly used when treating complex treatment-resistant psychotic disorders. Each medication guide contains sections including mechanisms of action, typical treatment response, monitoring, dosing and kinetics, medications to avoid in combination/warnings, and take-home pearls. Part III offers tips in brief appendix chapters for managing common issues ranging from loading lithium and valproic acid to the treatment of acute psychomotor agitation. An essential resource for psychiatrists, forensic clinicians, psychiatric trainees, and all mental health professionals involved with, or interested in, the treatment of challenging psychotic disorders.

• Presents a much-needed evidence-based psychopharmacological approach to the management of complex treatment-resistant psychotic disorders, covering important topics such as depressed and suicidal schizophrenic patients and the treatment of traumatic brain injuries and neurocognitive disorders
• Offers a compact, easily-accessible bank of information on the pharmacological agents most commonly used in treating complex treatment-resistant patients for both students and professionals
• Brief appendix chapters address the commonly encountered pharmacological issues involved in treating psychotic disorders

Table of Contents:

Part I. Treatment Strategies:

1.01. Approaches to positive Psychotic symptoms
1.02. Use of plasma levels in Antipsychotic and Mood Stabilizer treatment
1.03. Advantages of long-acting injectable Antipsychotics
1.04. Approach to Schizophrenia Spectrum treatment-resistant patients
1.05. Approach to depressed or suicidal Schizophrenia Spectrum patients
1.06. Approach to persistent aggression and violence in Schizophrenia Spectrum Disorders
1.07. Approach to treatment of Bipolar Diathesis in Schizophrenia Spectrum patients
1.08. Approach to Anxiety in Schizophrenia Spectrum patients
1.09. Approach to Insomnia and Sleep Disturbance in Schizophrenia Spectrum disorders
1.10. Approach to Psychosis in children and adolescents
1.11. Electro-convulsive therapy and other Non-pharmacological treatments
1.12. Approach to substance use disorders in Schizophrenia Spectrum Disorders
1.13. Approaches to Behavioral Disturbances and Dementia and TBI patients

Part II. Medication Reference Tables:

First-generation (Typical) Antipsychotics:
2.01. Chlorpromazine
2.02. Fluphenazine
2.03. Haloperidol
2.04. Loxapine
2.05. Perphenazine
2.06. Thiothixene
2.07. Trifluoperazine

Second-generation (Atypical) Antipsychotics:
2.08. Asenapine
2.09. Clozapine
2.10. Iloperidone
2.11. Lumateperone
2.12. Lurasidone
2.13. Olanzapine
2.14. Paliperidone
2.15. Quetiapine
2.16. Risperidone
2.17. Ziprasidone

Dopamine Partial Agonist Antipsychotics (Arias):
2.18. Aripiprazole
2.19. Brexpiprazole
2.20. Cariprazine

Medications for Motor/Neurologic Adverse Effects:
2.21. Amantadine
2.22. Benztropine
2.23. Diphenhydramine
2.24. Trihexyphenidyl

Mood Stabilizers:
2.25. Carbamazepine
2.26. Lamotrigine
2.27. Lithium
2.28. Valproic Acid

Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants:
2.29. Citalopram
2.30. Escitalopram
2.31. Fluoxetine
2.32. Fluvoxamine
2.33. Paroxetine
2.34. Sertraline: SSRI/5HT-1 Partial Agonist Antidepressants:
2.35. Vilazodone
2.36. Vortioxetine

Serotonin/Norepinephrine Reuptake Inhibitor (SNRI) Antidepressants
2.37. Desvenlafaxine
2.38. Duloxetine
2.39. Levomilnacipran
2.40. Venlafaxine

Mixed Mechanism Antidepressants:
2.41. Bupropion
2.42. Mirtazapine
2.43. Trazodone

Tricyclic Antidepressants:
2.44. Amitriptyline
2.45. Clomipramine
2.46. Desipramine
2.47. Doxepin
2.48. Imipramine
2.49. Nortriptyline

Monoamine Oxidase Inhibitor (MAOI) Antidepressants:
2.50. Isocarboxazid
2.51. Moclobemide
2.52. Phenelzine
2.53. Transdermal Segeliline
2.54. Tranylcypromine

Anxiolytics:
2.55. Alprazolam
2.56. Buspirone
2.57. Clonazepam
2.58. Diazepam
2.59. Hydroxyzine
2.60. Lorazepam

Sedatives:
2.61. Diphenhydramine
2.62. Eszopiclone
2.63. Hydroxyzine
2.64. Lorazepam
2.65. Oxazepam
2.66. Temazepam
2.67. Zaleplon
2.68. Zolpidem

Circadian Regulators:
2.69. Melatonin
2.70. Ramelteon
2.71. Tasimelteon

Stimulants:
2.72. Atomoxetine
2.73. Dextroamphetamine
2.74. Lisdexamphetamine
2.75. Methylphenidate
2.76. Mixed Amphetamine Salts: Histaminic Stimulants:
2.77. Armodafinil
2.78. Modafinil

Cognitive Agents:
2.79. Dextromethorphan/quinidine
2.80. Donepizil
2.81. Galantamine
2.82. Memantine
2.83. Rivastigmine

Alpha2-adrenergic Agonists:
2.84. Clonidine
2.85. Guanfacine

Appendices:
3.01. Optimal Antipsychotic Plasma Concentration Ranges
3.02. Optimal Mood Stabilizer Plasma Concentration Ranges
3.03. Formulas for QT Interval Correction
3.04. Common Cytochrome P-450 Inducers and Inhibitors
3.05. Management of Constipation
3.06. Child-Pugh Hepatic Function Scoring
3.07. Loading of Lithium and Valproic Acid
3.08. Treatment of Prolactin Elevation
3.09. A Select List of Foods High in Tyramine
3.10. Medications that Present Risk for Serotonin Syndrome when Combined with MAOIs
3.11. Selected Treatment of Psychomotor Agitation.


About the Editors:

Michael A. Cummings is Clinical Professor of Psychiatry at the University of California, Riverside, Associate Clinical Professor of Psychiatry at the University of California, Irvine and Senior Psychiatrist Specialist at the California Department of State Hospitals.

Stephen M. Stahl is Adjunct Professor of Psychiatry at the University of California, San Diego, Clinical Professor of Psychiatry and Neuroscience at the University of California, Riverside, and Honorary Visiting Senior Fellow in Psychiatry at the University of Cambridge.


Caversham Booksellers
98 Harbord St, Toronto, ON M5S 1G6 Canada
(click for map and directions)
All prices in $cdn
Copyright 2020

Phone toll-free (800) 361-6120
Tel (416) 944-0962 | Fax (416) 944-0963
E-mail [email protected]
Hours: 9-6 Mon-Sat / 12-5 Sun (EST)

search
Click here to read previous issues.
authors
Stahl, Stephen
other lists
Cambridge University Press
July 2021 New Arrivals
Newsletter-2021-12
Psychopharmacology